Biogen expects steady growth for Alzheimer’s drug Leqembi in near term

(Reuters) – Biogen expects growth of its keenly watched Alzheimer’s disease drug, Leqembi, to see a “linear trend” in the United States in the near term, a company executive said at a healthcare conference on Tuesday.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)